Anti-interleukin-1 treatment in patients with rheumatoid arthritis and type 2 diabetes (TRACK): A multicentre, open-label, randomised controlled trial
- Ruscitti P.
- Masedu F.
- Alvaro S.
- Airo P.
- Battafarano N.
- Cantarini L.
- Cantatore F. P.
- Carlino G.
- D'Abrosca V.
- Frassi M.
- Frediani B.
- Iacono D.
- Liakouli V.
- Maggio R.
- Mule R.
- Pantano I.
- Prevete I.
- Sinigaglia L.
- Valenti M.
- Viapiana O.
- Cipriani P.
- Giacomelli R.
Publication date
January 2019
DOI Publisher
Public Library of Science (PLoS)Abstract
The inflammatory contribution to type 2 diabetes (T2D) has suggested new therapeutic targets using biologic drugs designed for rheumatoid arthritis (RA). On this basis, we aimed at investigating whether interleukin-1 (IL-1) inhibition with anakinra, a recombinant human IL-1 receptor antagonist, could improve both glycaemic and inflammatory parameters in participants with RA and T2D compared with tumour necrosis factor (TNF) inhibitors (TNFis)
Add to ORKG